pharma · NSCLC
Formycon
Formycon AG
Formycon AG is a pharma organization headquartered in Planegg, DE. Primary therapeutic focus areas include NSCLC. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from
Planegg, DE HQ
2012 Founded
178 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Planegg, DE
- Founded
- 2012
- Employees
- 178
- Programs
- 2
- Drugs
- 4
- Patents
- 0
FYB206-C1-01
Phase 1 · other · Melanoma: Adjuvant treatment of patients with Stage IIB, IIC, or III melanoma following complete resection
FYB206-C1-01 for Melanoma: Adjuvant treatment of patients with Stage IIB, IIC, or III melanoma following complete resection is a Phase 1 program (other) at Formycon AG with 1 ClinicalTrials.gov record(s).
Internal code FYB206-C1-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Formycon AG
- Phase
- Phase 1
- Modality
- other
- Indication
- Melanoma: Adjuvant treatment of patients with Stage IIB, IIC, or III melanoma following complete resection
- Status
- active
- Trials
- 1